A clinical trial update for retatrutide (LY3437943) was recorded on September 25, 2026. The study, registered as NCT07035093, is titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain." This is a Phase 3 trial. Its current status is listed as active, not recruiting, meaning enrollment has closed while the study continues. The trial is evaluating retatrutide in participants who have obesity or overweight together with chronic low back pain. No results have been posted for this trial as of this update. The status change does not indicate any outcome, efficacy finding, or safety signal. It reflects only the progression of the trial through its stated phases as tracked on clinicaltrials.gov. Further updates may follow as the study proceeds toward completion or results posting. Readers interested in the compound can consult the retatrutide overview for additional context on its development and regulatory status.
Retatrutide Phase 3 Trial for Obesity, Low Back Pain Updated
See the full retatrutide overview
Source: https://clinicaltrials.gov/study/NCT07035093